The optimal therapy strategy for epidermal growth factor receptor‐mutated non‐small cell lung cancer patients with brain metastasis: A real‐world study from Taiwan
Background The treatment options for epidermal growth factor receptor (EGFR)‐mutated
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …
Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer
H Wang, X Yu, Y Fan, Y Jiang - OncoTargets and therapy, 2018 - Taylor & Francis
Background There are many controversies concerning the best management of epidermal
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients with …
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients with …
Real‐world utilization of EGFR TKIs and prognostic factors for survival in EGFR‐mutated non‐small cell lung cancer patients with brain metastases
X Yu, J Sheng, G Pan, Y Fan - International Journal of Cancer, 2021 - Wiley Online Library
Brain metastases (BMs) cause morbidity and mortality in patients with non‐small cell lung
cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR) …
cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR) …
Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor …
L Zhang, Y You, X Liu, F Liu, K Nie, Y Ji - Thoracic Cancer, 2023 - Wiley Online Library
Background The efficacy and safety of osimertinib combined with bevacizumab in non‐small
cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor …
cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor …
Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 …
Simple Summary Radiotherapy, in the form of either whole-brain radiotherapy (WBRT) or
stereotactic radiosurgery (SRS), continues as the standard of care for patients of non-small …
stereotactic radiosurgery (SRS), continues as the standard of care for patients of non-small …
[HTML][HTML] Real-world data on prognostic factors for overall survival in EGFR-mutant non-small-cell lung cancer patients with brain metastases
X Yu, Y Fan - Journal of Cancer, 2019 - ncbi.nlm.nih.gov
Background: With the wide application of epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs), the survival of EGFR-mutant non-small-cell lung cancer (NSCLC) …
inhibitors (EGFR-TKIs), the survival of EGFR-mutant non-small-cell lung cancer (NSCLC) …
First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and …
Y Song, S Lin, J Chen, J Dang - BMC cancer, 2023 - Springer
Background It remains uncertain whether first-line treatment with upfront brain radiotherapy
(RT) in combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR …
(RT) in combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR …
EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data
Y Fan, X Xu, C Xie - OncoTargets and therapy, 2014 - Taylor & Francis
Introduction Brain metastases are one of the leading causes of death from non-small-cell
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …
Management of brain metastases in tyrosine kinase inhibitor–naïve epidermal growth factor receptor–mutant non–small-cell lung cancer: a retrospective multi …
WJ Magnuson, NH Lester-Coll, AJ Wu… - Journal of clinical …, 2017 - ascopubs.org
Purpose Stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and epidermal
growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are treatment options for …
growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are treatment options for …
Different tyrosine kinase inhibitors used in treating EGFR-mutant pulmonary adenocarcinoma with brain metastasis and intracranial intervention have no impact on …
Simple Summary Brain metastasis is a factor of a poor prognosis in patients with non-small-
cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations …
cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations …